Inventor · disambiguated record
Kevin Slawin
Also filed as: SLAWIN KEVIN · SLAWIN KEVIN M
15 granted patents·22 pending applications·280 citations·filing 1997–2021
94Inventor score
Files withBELLICUM PHARMACEUTICALS INC15BAYLOR COLLEGE MEDICINE9HYBRITECH INC2BAYLOR COLLEGE OF MEDICINE BY1BAYLOR COLLEGE OF MEDICINE HYB1
Top patents by PatentIndex Score
37 records- 0196US8999949B2Induced activation in dendritic cellsBAYLOR COLLEGE MEDICINE·Filed 2013·Granted Apr 7, 2015·36 cites·19 claims
- 0294US8771671B2Induced activation in dendritic cellsSPENCER DAVID·Filed 2008·Granted Jul 8, 2014·35 cites·40 claims
- 0394US7404950B2Induced activation in dendritic cellBAYLOR COLLEGE MEDICINE·Filed 2004·Granted Jul 29, 2008·58 cites·52 claims
- 0493US10888608B2Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptidesBELLICUM PHARMACEUTICALS INC·Filed 2015·Granted Jan 12, 2021·8 cites·16 claims
- 0590US9913882B2Methods for inducing partial apoptosis using caspase polypeptidesBELLICUM PHARMACEUTICALS INC·Filed 2014·Granted Mar 13, 2018·16 cites·57 claims
- 0689US9944690B2Methods for controlling T cell proliferationBELLICUM PHARMACEUTICALS INC·Filed 2014·Granted Apr 17, 2018·14 cites·15 claims
- 0788US9572835B2Induced activation in dendritic cellsBAYLOR COLLEGE MEDICINE·Filed 2015·Granted Feb 21, 2017·5 cites·13 claims
- 0885US10525110B2Methods for inducing partial apoptosis using caspase polypeptidesBELLICUM PHARMACEUTICALS INC·Filed 2018·Granted Jan 7, 2020·4 cites·33 claims
- 0983US10918705B2Costimulation of chimeric antigen receptors by MYD88 and CD40 polypeptidesBELLICUM PHARMACEUTICALS INC·Filed 2020·Granted Feb 16, 2021·1 cites·22 claims
- 1083US6479263B1Method for detection of micrometastatic prostate cancerBAYLOR COLLEGE MEDICINE·Filed 1997·Granted Nov 12, 2002·50 cites·10 claims
- 1180US10934346B2Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12BELLICUM PHARMACEUTICALS INC·Filed 2015·Granted Mar 2, 2021·5 cites·15 claims
- 1277US10420824B2Induced activation in dendritic cellsBAYLOR COLLEGE MEDICINE·Filed 2017·Granted Sep 24, 2019·1 cites·16 claims
- 1377US2022233670A1Induced activation in dendritic cellsBAYLOR COLLEGE MEDICINE·Filed 2021·Application pending·0 cites
- 1476US2020197502A1Induced activation in dendritic cellsBAYLOR COLLEGE MEDICINE·Filed 2019·Application pending·0 cites
- 1568US6482599B1Forms of prostate specific antigen (PSA) specific for benign prostatic hyperplasia (BPH) and methods of using suchHYBRITECH INC·Filed 1999·Granted Nov 19, 2002·20 cites·46 claims
- 1667US11839647B2Methods for inducing partial apoptosis using caspase polypeptidesBELLICUM PHARMACEUTICALS INC·Filed 2020·Granted Dec 12, 2023·0 cites·25 claims
- 1765US2021346477A1Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptidesBELLICUM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1863US6423503B1Forms of free prostate-specific antigen (PSA) and their association with prostate tissues from prostate peripheral zone and transition zoneHYBRITECH INC·Filed 1999·Granted Jul 23, 2002·27 cites·38 claims
- 1957US2022125837A1Methods for controlled elimination of therapeutic cellsBELLICUM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2056US2014023647A1Method for treating solid tumorsBELLICUM PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 2156US2022152100A1Methods for controlled activation or elimination of therapeutic cellsBELLICUM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2255US2022025024A1Methods for activating t cells using an inducible chimeric polypeptideBELLICUM PHARMACEUTICS INC·Filed 2021·Application pending·0 cites
- 2354US2003119033A1Novel forms of prostate specific antigen (PSA) specific for benign prostatic hyperplasia (BPH) and methods of using suchHYBRITECH INC AND BAYLOR COLLE·Filed 2002·Application pending·0 cites
- 2452US2003113743A1Method for detection of micrometastatic prostate cancerBAYLOR COLLEGE OF MEDICINE HYB·Filed 2002·Application pending·0 cites
- 2551US2011287038A1Method for treating solid tumorsSLAWIN KEVIN·Filed 2011·Application pending·0 cites
- 2649US2018265566A1Methods for controlling t cell proliferationBELLICUM PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2748US2009123501A1Inhibition of the sh2-domain containing protein tyr-phosphatase, shp-1, to enhance vaccinesBAYLOR COLLEGE MEDICINE·Filed 2008·Application pending·0 cites
- 2846US2004040047A1Regulated apoptosis using chemically induced dimerization of apoptosis factorsFiled 2002·Application pending·0 cites
- 2943US2007134725A1Method to predict risk of bph progressionSLOAN KETTERING INST CANCER·Filed 2006·Application pending·0 cites
- 3042US2006194230A1Genetic markers associated with benign prostatic hyperplasiaBAYLOR COLLEGE MEDICINE·Filed 2006·Application pending·0 cites
- 3139US2005282199A1Method to predict prostate cancerSLAWIN KEVIN M·Filed 2005·Application pending·0 cites
- 3237US2016166613A1Methods for controlled elimination of therapeutic cellsBELLICUM PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 3336US2003235816A1Method to determine outcome for patients with prostatic diseaseBAYLOR COLLEGE OF MEDICINE BY·Filed 2003·Application pending·0 cites
- 3435US2016175359A1Methods for controlled activation or elimination of therapeutic cellsBELLICUM PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 3533US2015328292A1Caspase polypeptides having modified activity and uses thereofBELLICUM PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 3631US2003054419A1Method to determine prognosis after therapy for prostate cancerFiled 2002·Application pending·0 cites
- 3731US2003032074A1Methods to determine prognosis after therapy for bladder cancerFiled 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Kevin Slawin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →